Alethia Biotherapeutics is a clinical-stage biotechnology company focused on overcoming immune suppression and treatment resistance in metastatic cancers. Its lead candidate, sotevtamab (AB-16B5), targets epithelial-to-mesenchymal transition (EMT), a key driver of metastasis and immune evasion. By inhibiting EMT-associated resistance pathways and promoting a more immunologically active tumor environment, Alethia aims to improve the depth and durability of patient responses to therapy.
Hybride · Montréal
The Clinical Trial Manager is responsible for the operational execution of Phase 2 oncology studies, from site activation to closure. This includes supervising CRAs, managing CROs and external partners, and ensuring the trial master file is inspection-ready.